Literature DB >> 23118212

Gene therapy for ADA-SCID: defining the factors for successful outcome.

H Bobby Gaspar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23118212     DOI： 10.1182/blood-2012-08-446559

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.

Authors:  Makoto Otsu; Masafumi Yamada; Satoru Nakajima; Miyuki Kida; Yoshihiro Maeyama; Norikazu Hatano; Nariaki Toita; Shunichiro Takezaki; Yuka Okura; Ryoji Kobayashi; Yoshinori Matsumoto; Osamu Tatsuzawa; Fumiko Tsuchida; Shunichi Kato; Masanari Kitagawa; Junichi Mineno; Michael S Hershfield; Pawan Bali; Fabio Candotti; Masafumi Onodera; Nobuaki Kawamura; Yukio Sakiyama; Tadashi Ariga
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

2.  Inborn errors of purine metabolism: clinical update and therapies.

Authors:  Shanti Balasubramaniam; John A Duley; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2014-06-28       Impact factor: 4.982

Review 3.  The case for mandatory newborn screening for severe combined immunodeficiency (SCID).

Authors:  H B Gaspar; L Hammarström; N Mahlaoui; M Borte; S Borte
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

4.  Primary Immune Deficiency Treatment Consortium (PIDTC) report.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; Sung-Yun Pai; Barbara Ballard; Sarah C Bauer; Jack J H Bleesing; Marcia Boyle; Amy Brower; Rebecca H Buckley; Mirjam van der Burg; Lauri M Burroughs; Fabio Candotti; Andrew J Cant; Talal Chatila; Charlotte Cunningham-Rundles; Mary C Dinauer; Christopher C Dvorak; Alexandra H Filipovich; Thomas A Fleisher; Hubert Bobby Gaspar; Tayfun Gungor; Elie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary Hurley; Sumathi Iyengar; Elizabeth M Kang; Brent R Logan; Janel R Long-Boyle; Harry L Malech; Sean A McGhee; Fred Modell; Vicki Modell; Hans D Ochs; Richard J O'Reilly; Robertson Parkman; David J Rawlings; John M Routes; William T Shearer; Trudy N Small; Heather Smith; Kathleen E Sullivan; Paul Szabolcs; Adrian Thrasher; Troy R Torgerson; Paul Veys; Kenneth Weinberg; Juan Carlos Zuniga-Pflucker
Journal:  J Allergy Clin Immunol       Date:  2013-10-15       Impact factor: 10.793

Review 5.  Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point of View.

Authors:  Marina Cavazzana; Jean-Antoine Ribeil; Chantal Lagresle-Peyrou; Isabelle André-Schmutz
Journal:  Stem Cells Dev       Date:  2016-10-16       Impact factor: 3.272

Review 6.  Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders.

Authors:  Arome Solomon Odiba; Nkwachukwu Oziamara Okoro; Olanrewaju Ayodeji Durojaye; Yanjun Wu
Journal:  Open Life Sci       Date:  2021-05-03       Impact factor: 0.938

Review 7.  Gene therapy on the move.

Authors:  Kerstin B Kaufmann; Hildegard Büning; Anne Galy; Axel Schambach; Manuel Grez
Journal:  EMBO Mol Med       Date:  2013-09-17       Impact factor: 12.137

Review 8.  Clinical development of gene therapy: results and lessons from recent successes.

Authors:  Sandeep Rp Kumar; David M Markusic; Moanaro Biswas; Katherine A High; Roland W Herzog
Journal:  Mol Ther Methods Clin Dev       Date:  2016-05-25       Impact factor: 6.698
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.